INTELLIA THERAPEUTICS INC. - COMMON STOCK

10.20

10-January-25 15:45:00

15 minutes delayed

Stocks

-1.82

-15.14%

Today's range

9.93 - 11.43

ISIN

N/A

Source

NASDAQ

Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors

02 May 2022 15:01:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference

02 May 2022 06:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company Updates

28 Apr 2022 06:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia

09 Mar 2022 15:01:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for the Treatment of Acute Myeloid Leukemia

01 Mar 2022 06:30:00 By Nasdaq GlobeNewswire
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

28 Feb 2022 15:01:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress

24 Feb 2022 06:30:01 By Nasdaq GlobeNewswire
Intellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based Therapies

23 Feb 2022 07:00:02 By Nasdaq GlobeNewswire
Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022

17 Feb 2022 06:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics

03 Feb 2022 06:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022

06 Jan 2022 06:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

05 Jan 2022 15:01:00 By Nasdaq GlobeNewswire
Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases

05 Jan 2022 06:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer

20 Dec 2021 06:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

13 Dec 2021 06:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)

22 Nov 2021 06:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting

05 Nov 2021 06:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

04 Nov 2021 06:30:01 By Nasdaq GlobeNewswire
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company Updates

28 Oct 2021 06:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis

21 Oct 2021 06:30:00 By Nasdaq GlobeNewswire

<<
<
2
3
4
5
6
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.